# Study of ZKAB001 for Maintenance Therapy in Patients With High-grade Osteosarcoma After Adjuvant Chemotherapy

> **NCT04359550** · PHASE3 · UNKNOWN · sponsor: **Lee's Pharmaceutical Limited** · enrollment: 362 (estimated)

## Conditions studied

- High-grade Osteosarcoma

## Interventions

- **BIOLOGICAL:** Recombinant human anti-PD-L1 monoclonal antibody (ZKAB001)
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT04359550
- **Lead sponsor:** Lee's Pharmaceutical Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-01
- **Primary completion:** 2022-06-01
- **Final completion:** 2023-06-01
- **Target enrollment:** 362 (ESTIMATED)
- **Last updated:** 2020-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04359550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04359550, "Study of ZKAB001 for Maintenance Therapy in Patients With High-grade Osteosarcoma After Adjuvant Chemotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04359550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*